PathWhiz ID | Pathway | Meta Data |
---|---|---|
PW128268View Pathway |
drug action
Pitavastatin Action PathwayHomo sapiens
Pitavastatin, also known as Livalo, is an hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor. This drug is a lipid-lowering drug belonging to the statin class of medications. The inhibited enzyme is catalyzing the conversion of HMG-CoA to mevalonic acid, the third step of the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL), and very low-density lipoprotein (VLDL). This drug is indicated for the treatment of hyperlipidemia or mixed dyslipidemia to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C). Statin medication prescriptions can be given following any cardiovascular events and to people with a moderate risk of development of CVD. Pitavastatin mainly operates within the liver, where it prompts the liver to increase the production of low-density lipoprotein (LDL) receptors due to lowered cholesterol levels. This rise in the production of receptors enhances the liver's ability to absorb LDL, leading to a reduction in circulating LDL-C levels. This drug is administered as an oral tablet.
|
Creator: Daphnee Created On: August 11, 2023 at 16:04 Last Updated: August 11, 2023 at 16:04 |
PW145853View Pathway |
drug action
Pitavastatin Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 16:49 Last Updated: October 07, 2023 at 16:49 |
PW146418View Pathway |
drug action
Pitolisant Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 18:09 Last Updated: October 07, 2023 at 18:09 |
PW176951View Pathway |
drug action
Pivampicillin Action PathwayEscherichia coli
Pivampicillin is a 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics.5 It was first authorized for use in the US in November 2001 and in Europe in April 2002. Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to treat various bacterial infections. Pivampicillin exhibits a bactericidal mode of action. It works by binding to and inhibiting bacterial penicillin-binding proteins (PBPs).5 In Escherichia coli, it has a strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preferential binding to PBPs 2 and 3.5 Upon binding to PBPs, ertapenem inhibits bacterial cell wall synthesis by interfering with the lengthening and strengthening of the peptidoglycan portion of the cell wall, thereby inhibiting cell wall synthesis.
|
Creator: Karxena Harford Created On: January 02, 2024 at 09:19 Last Updated: January 02, 2024 at 09:19 |
PW145471View Pathway |
drug action
Pivampicillin Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 15:53 Last Updated: October 07, 2023 at 15:53 |
PW176952View Pathway |
drug action
Pivmecillinam Action PathwayEscherichia coli
Pivmecillinam is a 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics.5 It was first authorized for use in the US in November 2001 and in Europe in April 2002. Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to treat various bacterial infections. Pivmecillinam exhibits a bactericidal mode of action. It works by binding to and inhibiting bacterial penicillin-binding proteins (PBPs).5 In Escherichia coli, it has a strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preferential binding to PBPs 2 and 3.5 Upon binding to PBPs, ertapenem inhibits bacterial cell wall synthesis by interfering with the lengthening and strengthening of the peptidoglycan portion of the cell wall, thereby inhibiting cell wall synthesis.
|
Creator: Karxena Harford Created On: January 02, 2024 at 09:19 Last Updated: January 02, 2024 at 09:19 |
PW145472View Pathway |
drug action
Pivmecillinam Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 15:54 Last Updated: October 07, 2023 at 15:54 |
PW128555View Pathway |
drug action
Pixantrone Action PathwayHelicobacter pylori
Pixantrone is anaza-anthracenedione and DNA intercalator which inhibits topoisomerase II, used to treat patients with relapsed or refractory aggressive Non-Hodgkin B-cell Lymphomas
Pixantrone inhibits DNA gyrase (topoisomerase II). DNA gyrase prevents supercoiling in bacterial DNA. The inhibition of DNA gyrase (topoisomerase II) and topoisomerase IV causes supercoiling of the bacterial DNA. This prevents DNA replication.
|
Creator: Ray Kruger Created On: September 02, 2023 at 17:56 Last Updated: September 02, 2023 at 17:56 |
PW145670View Pathway |
drug action
Pixantrone Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 16:21 Last Updated: October 07, 2023 at 16:21 |
PW176285View Pathway |
Pixantrone Predicted Metabolism PathwayHomo sapiens
Metabolites of Pixantrone are predicted with biotransformer.
|
Creator: Omolola Created On: December 04, 2023 at 14:40 Last Updated: December 04, 2023 at 14:40 |